SLNO Stock Price, Soleno Therapeutics Inc Quote, Chart

Market Summary

USD37.27-2.07

Market Closed

-5.26%

SLNO Alerts

2 major insider sales recently.

SLNO Stock Price

View Fullscreen

SLNO RSI Chart

SLNO Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-32.75

Price/Sales (Trailing)

1.0K

EV/EBITDA

-29.9

Price/Free Cashflow

-51.2

SLNO Price/Sales (Trailing)

SLNO Profitability

Operating Margin

26.92%

EBT Margin

-816.18%

Return on Equity

-24.75%

Return on Assets

-21.58%

Free Cashflow Yield

-1.95%

SLNO Fundamentals

SLNO Revenue

Revenue (TTM)

1.5M

SLNO Earnings

Earnings (TTM)

-39.0M

Earnings Growth (Yr)

-105.91%

Earnings Growth (Qtr)

-4.01%

Breaking Down SLNO Revenue

Last 7 days

4.0%

Last 30 days

-5.4%

Last 90 days

-15.8%

Trailing 12 Months

965.4%

How does SLNO drawdown profile look like?

SLNO Financial Health

Current Ratio

14.89

SLNO Investor Care

Shares Dilution (1Y)

297.37%

Diluted EPS (TTM)

-2.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2017	0	0	0	0
2016	812.6K	1.0M	1.2M	1.5M
2015	2.3M	1.7M	1.0M	387.6K
2013	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Soleno Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	anish bhatnagar	sold	-784,645	41.3406	-18,980	chief executive officer
Apr 01, 2024	yen kristen	sold	-91,693	41.3407	-2,218	see remarks
Apr 01, 2024	mackaness james h	sold	-213,937	41.3406	-5,175	chief financial officer
Apr 01, 2024	hirano patricia c	sold	-91,693	41.3407	-2,218	see remarks
Jan 25, 2024	anish bhatnagar	sold	-122,054	48.3	-2,527	chief executive officer
Jan 25, 2024	yen kristen	sold	-19,175	48.3	-397	see remarks
Jan 25, 2024	hirano patricia c	sold	-40,185	48.3	-832	see remarks
Jan 08, 2024	mario ernest	gifted	-	-	-3,523	-
Jan 04, 2024	anish bhatnagar	acquired	-	-	150,000	chief executive officer
Jan 04, 2024	yen kristen	acquired	-	-	24,000	see remarks

Which funds bought or sold SLNO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	new	-	2,996	2,996	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	21,466,100	360,294,000	28.31%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	new	-	4,444,310	4,444,310	0.01%
Apr 17, 2024	Cannon Global Investment Management, LLC	new	-	505,040	505,040	1.36%
Apr 15, 2024	ASPIRIANT, LLC	unchanged	-	30,926	519,078	0.02%
Mar 11, 2024	VANGUARD GROUP INC	added	1,654	37,396,800	39,027,300	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	5,522,220	5,522,220	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	33,020,600	123,750,000	2.76%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	new	-	201	201	-%
Feb 15, 2024	Legal & General Group Plc	new	-	311,012	311,012	-%

Are Funds Buying or Selling SLNO?

Are funds buying SLNO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLNO

No. of Funds

SLNO Alerts

2 major insider sales recently.

Unveiling Soleno Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	commodore capital lp	2.3%	7e+05	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	3,068,031	SC 13G/A
Feb 13, 2024	janus henderson group plc	8.3%	2,523,897	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	5.99%	1,826,814	SC 13G/A
Oct 23, 2023	perceptive advisors llc	10.1%	3,074,542	SC 13D/A
Oct 16, 2023	carlyle group inc.	9.99%	2,893,615	SC 13D/A
Oct 12, 2023	commodore capital lp	6.0%	885,741	SC 13G
Oct 12, 2023	adage capital partners gp, l.l.c.	8.69%	1,327,000	SC 13G
Oct 11, 2023	vivo opportunity fund holdings, l.p.	30.5%	8,418,093	SC 13D/A
Oct 10, 2023	fairmount funds management llc	6.2%	950,000	SC 13G

Recent SEC filings of Soleno Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 07, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Soleno Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Soleno Therapeutics Inc News

Latest updates

Soleno Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2013Q4	2013Q3
Revenue	-97.0%	4,000	134,500	265,000	283,788	329,000	388,000	447,000	21,555	247,000	97,000	-	-	-
Cost Of Revenue	-100.0%	-	42,000	209,000	410,306	399,000	51,000	461,000	256,683	56,000	22,000	18,000	-	-
Gross Profit	100.0%	-	-41,000	56,000	67,982	-70,000	-49,000	-14,000	-15,211	191,000	75,000	4,000	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-1,000	-	-	1,000	-	571,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	184.3%	181	64.00	31.00	20.00	26.00	32.00	37.00	43.00	36.00	43.00	49.00	57.00	65.00	72.00	79.00	32.00	38.00	29.00	34.00	39.00	43.00
Current Assets	219.3%	171	54.00	20.00	9.00	16.00	21.00	25.00	30.00	22.00	29.00	35.00	43.00	50.00	56.00	63.00	16.00	21.00	12.00	17.00	21.00	25.00
Cash Equivalents	223.6%	170	52.00	19.00	8.00	15.00	20.00	24.00	29.00	21.00	28.00	34.00	42.00	49.00	56.00	62.00	15.00	21.00	11.00	16.00	19.00	23.00
Net PPE	-20.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-42.5%	23.00	40.00	19.00	17.00	16.00	17.00	17.00	16.00	18.00	22.00	21.00	19.00	19.00	24.00	23.00	23.00	23.00	14.00	20.00	15.00	13.00
Current Liabilities	-60.3%	12.00	29.00	9.00	8.00	7.00	7.00	7.00	7.00	8.00	9.00	8.00	10.00	9.00	8.00	8.00	7.00	5.00	3.00	3.00	2.00	2.00
Shareholder's Equity	578.3%	158	23.00	12.00	3.00	10.00	15.00	20.00	26.00	18.00	20.00	27.00	38.00	46.00	48.00	56.00	9.00	15.00	15.00	14.00	24.00	30.00
Retained Earnings	-4.3%	-276	-265	-254	-245	-237	-231	-225	-219	-213	-210	-202	-191	-182	-179	-171	-163	-157	-143	-144	-134	-127
Additional Paid-In Capital	50.5%	434	288	267	248	248	247	246	245	231	231	230	229	228	228	227	173	173	158	158	158	157
Accumulated Depreciation	-	0.00	-	-	-	0.00	-	-	-	0.00	-	-	-	0.00	-	-	-	0.00	-	-	-	0.00
Shares Outstanding	104.8%	32.00	15.00	9.00	8.00	8.00	8.00	9.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	33.00	-	-	-	8.00	-	-	-	61.00	-	-	-	98.00	-	-	-	28.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-0.5%	-6,340	-6,306	-5,594	-6,700	-5,143	-4,656	-4,620	-6,362	-6,863	-5,406	-8,013	-7,488	-6,867	-6,164	-6,534	-5,659	-5,076	-4,719	-3,893	-3,687	-3,736
Share Based Compensation	-13.3%	1,909	2,201	1,204	631	632	683	571	644	418	906	857	1,095	393	374	341	392	204	153	220	248	532
Cashflow From Investing	-	-	-	-	-	-6.00	-	-	-	-13.00	-5.00	-	-4.00	-4.00	-	-	-	103	441	-6.00	-10.00	-174
Cashflow From Financing	213.6%	123,558	39,401	-	-	-	342	-282	14,032	-5.00	-	2.00	-125	-42.00	-195	53,963	-4.00	-	-	-	-	16,302

SLNO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 25,189	$ 15,265
General and administrative	13,481	9,844
Change in fair value of contingent consideration	2,714	(712)
Total operating expenses	41,384	24,397
Operating loss	(41,384)	(24,397)
Other income (expense), net
Change in fair value of warrant liability	(182)	30
Interest income	2,578	300
Total other income (expense), net	2,396	330
Net loss	$ (38,988)	$ (24,067)
Net loss per common share basic	$ (2.36)	$ (2.87)
Net loss per common share diluted	$ (2.36)	$ (2.87)
Weighted-average common shares outstanding used to calculate basic net loss per common share	16,492,132	8,397,088
Weighted-average common shares outstanding used to calculate diluted net loss per common share	16,492,132	8,397,088

SLNO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 169,681	$ 14,602
Prepaid expenses and other current assets	1,677	1,045
Total current assets	171,358	15,647
Long-term assets
Property and equipment, net	12	26
Operating lease right-of-use assets	407	131
Intangible assets, net	8,749	10,693
Other long-term assets	165
Total assets	180,691	26,497
Current liabilities
Accounts payable,net	3,149	1,777
Accrued compensation	3,135	1,675
Accrued clinical trial site costs	3,393	3,222
Operating lease liabilities	273	155
Other current liabilities	1,555	484
Total current liabilities	11,505	7,313
Long-term liabilities
Contingent liability for Essentialis purchase price	11,549	8,835
Long-term lease liabilities	130	0
Total liabilities	23,184	16,149
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 31,678,159 and 8,159,382 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively.	32	8
Additional paid-in-capital	433,885	247,762
Accumulated deficit	(276,410)	(237,422)
Total stockholders' equity	157,507	10,348
Total liabilities and stockholders'equity	180,691	26,497
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 0	$ 1

About Soleno Therapeutics Inc

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

CEO	Dr. Anish Bhatnagar M.D.
WEBSITE	https://soleno.life
INDUSTRY	Biotechnology
EMPLOYEES	25

Soleno Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Soleno Therapeutics Inc? What does SLNO stand for in stocks?

SLNO is the stock ticker symbol of Soleno Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Soleno Therapeutics Inc (SLNO)?

As of Wed Apr 24 2024, market cap of Soleno Therapeutics Inc is 1.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLNO stock?

You can check SLNO's fair value in chart for subscribers.

What is the fair value of SLNO stock?

You can check SLNO's fair value in chart for subscribers. The fair value of Soleno Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Soleno Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLNO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Soleno Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SLNO is over valued or under valued. Whether Soleno Therapeutics Inc is cheap or expensive depends on the assumptions which impact Soleno Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLNO.

What is Soleno Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, SLNO's PE ratio (Price to Earnings) is -32.75 and Price to Sales (PS) ratio is 1 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLNO PE ratio will change depending on the future growth rate expectations of investors.